Cardiovascular toxicity of valdecoxib.

@article{Ray2004CardiovascularTO,
  title={Cardiovascular toxicity of valdecoxib.},
  author={W. A. Ray and Marie R. Griffin and Charles Michael Stein},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 26},
  pages={
          2767
        }
}
To the Editor: Rofecoxib (Vioxx) was recently withdrawn from the market because of an increased risk of myocardial infarction and stroke. There is a similar public health concern about another coxib, valdecoxib (Bextra), which is used by 7 million patients worldwide.1 To protect the safety of the public, we write to recommend that clinicians stop prescribing valdecoxib except in extraordinary circumstances. This recommendation is based on the long delay between the initial evidence of the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Efficacy of pulsed radiofrequency treatment on the saphenous nerve in patients with chronic knee pain.

  • Journal of back and musculoskeletal rehabilitation
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND

Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2010
VIEW 1 EXCERPT
CITES BACKGROUND